Vidara Therapeutics Inc. Announces the launch of a Clinical Nurse Program for patients with Chronic Granulomatous Disease (CGD) or Severe, Malignant Osteopetrosis

February 2014

Vidara Therapeutics Inc. is pleased to announce the latest enhancement to the COMPASS™ program for patients with Chronic Granulomatous Disease (CGD) or severe, malignant osteopetrosis, and who are taking ACTIMMUNE®.

The Clinical Nurse Program will provide patients and caregivers the opportunity to connect with a Registered Nurse who can provide disease-state education, ACTIMMUNE® treatment guidance, and support to patients and caregivers managing CGD or severe, malignant osteopetrosis.

The program offers various learning opportunities, which can be tailored to the needs and interests of the patient. The Registered Nurse can provide information and resources on a variety of areas, including understanding your disease, injection training and lifestyle management. In addition, if patients or caregivers need assistance learning to give ACTIMMUNE®, the Clinical Nurse Program can send a Registered Nurse to the patient’s home to teach the patient or caregiver how to appropriately administer ACTIMMUNE®.

Vidara is committed to providing support to patients & families living with CGD and severe, malignant osteopetrosis. For more information regarding the COMPASS™ Program support services available for CGD and severe, malignant osteopetrosis patients, families and healthcare providers, call 877-305-7704, or visit www.compassforpatients.com.

For more information on ACTIMMUNE®, please see the Full Prescribing Information at actimmune.com, or call 877-305-7704. Please see the Important Safety Information below for ACTIMMUNE®.

**Important Safety Information**

ACTIMMUNE® (Interferon gamma-1b) is indicated for:

**Indications and Usage**

**Chronic Granulomatous Disease (CGD)**

ACTIMMUNE® is approved by the US Food and Drug Administration to reduce the frequency and severity of serious infections associated with Chronic Granulomatous Disease. CGD is a genetic disorder that affects the functioning of some cells of the immune system.

**Severe, Malignant Osteopetrosis (SMO)**

ACTIMMUNE® is approved by the US Food and Drug Administration to slow the worsening of severe, malignant osteopetrosis. SMO is also a genetic disorder that affects normal bone formation.
Important Safety Information (ISI)

ACTIMMUNE® is contraindicated in patients who develop or have known hypersensitivity to interferon-gamma, *E. coli*-derived products, or any component of the product.

The most common adverse experiences occurring with ACTIMMUNE® therapy are “flu-like”, or constitutional symptoms such as fever, headache, chills, myalgia, or fatigue, which may decrease in severity as treatment continues. Some of the “flu-like” symptoms may be minimized by bedtime administration of ACTIMMUNE®. Acetaminophen may be used to prevent or partially alleviate the fever and headache.

Reversible neutropenia and thrombocytopenia have been observed during ACTIMMUNE® therapy. Caution should be exercised when administering ACTIMMUNE® in patients with myelosuppression or in combination with other potentially myelosuppressive agents.

Reversible elevations of AST and/or ALT have been observed during ACTIMMUNE® therapy. Patients begun on ACTIMMUNE® therapy before one year of age should receive monthly assessments of liver function. If severe hepatic enzyme elevations develop, ACTIMMUNE® dosage should be modified.

At doses 10 times greater than the weekly recommended dose, ACTIMMUNE® may exacerbate pre-existing cardiac conditions or may cause reversible neurological effects such as decreased mental status, gait disturbance and dizziness. Therefore, caution is advised when ACTIMMUNE® is administered to patients with seizure disorders or compromised CNS function or when administered to patients with cardiac conditions such as ischemia, heart failure or arrhythmia.

If you are pregnant or plan to become pregnant you should consult with your physician.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

This information is not intended to replace discussions with your doctor. For additional information about ACTIMMUNE®, please consult the Full Prescribing Information and the Information for the Patient/Caregiver and talk to your doctor. ACTIMMUNE® is available by prescription only.

Download a copy of the ACTIMMUNE® Full Prescribing Information.